Research Analysts Offer Predictions for ESPR Q2 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Zacks Research lowered their Q2 2026 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Tuesday, March 31st. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of ($0.02) for the quarter, down from their previous forecast of ($0.01). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q3 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.04) EPS, Q3 2027 earnings at ($0.03) EPS, Q4 2027 earnings at $0.08 EPS, FY2027 earnings at $0.21 EPS and Q1 2028 earnings at $0.14 EPS.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.01). The company had revenue of $168.45 million during the quarter, compared to analyst estimates of $165.12 million.

Several other equities analysts have also recently weighed in on the stock. Needham & Company LLC raised their target price on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Citizens Jmp upped their price target on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research report on Friday, March 13th. Wall Street Zen upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating on shares of Esperion Therapeutics in a research note on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.60.

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock opened at $2.61 on Thursday. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $4.18. The stock has a market cap of $670.27 million, a P/E ratio of -15.35, a P/E/G ratio of 2.12 and a beta of 1.17. The business’s 50 day moving average is $3.07 and its 200-day moving average is $3.16.

Institutional Investors Weigh In On Esperion Therapeutics

Several hedge funds have recently added to or reduced their stakes in ESPR. R Squared Ltd boosted its stake in Esperion Therapeutics by 23.5% in the 4th quarter. R Squared Ltd now owns 15,173 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 2,890 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Esperion Therapeutics by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 38,955 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 3,614 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Esperion Therapeutics by 49.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 3,822 shares in the last quarter. Eaton Financial Holdings Company LLC lifted its holdings in shares of Esperion Therapeutics by 9.4% during the fourth quarter. Eaton Financial Holdings Company LLC now owns 46,595 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 4,000 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of Esperion Therapeutics by 18.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,338 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 4,422 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.

Trending Headlines about Esperion Therapeutics

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Closed acquisition of Corstasis Therapeutics, adding Enbumyst™ (bumetanide nasal spray) — Esperion says the FDA‑approved product will be integrated into its cardiovascular franchise to expand the portfolio, enable commercial leverage and support revenue growth prospects. This is a strategic, revenue‑accretive product addition that can improve commercial scale. Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics
• Positive Sentiment: $50 million royalty financing with Athyrium — Athyrium will acquire Esperion’s royalty interest in Otsuka’s Japan sales of bempedoic acid products (and related milestones) beginning Jan 1, 2026, providing immediate, non‑dilutive cash to support the Corstasis acquisition and other initiatives. The deal reduces near‑term financing risk and supplies capital for commercialization. Note: Esperion sells future royalty upside (subject to a cap), which lowers future upside from Japan royalty streams. Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing
• Neutral Sentiment: Media roundup noting mixed analyst sentiment — coverage highlights differing analyst views on Esperion’s prospects, reflecting the market’s split reaction to the acquisition/financing versus earnings revisions. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Negative Sentiment: Multiple near‑term earnings cuts from Zacks Research — analysts trimmed Q2–Q3 2026 and several 2027 quarterly estimates and reduced FY2026 and FY2027 forecasts (e.g., FY2026 now modeled at -$0.04 vs prior -$0.01; FY2027 cut to $0.21 from $0.26). While some later‑year estimates (Q1/Q2 2027 and FY2028) were raised, the predominant message is weaker near‑term profitability, which can pressure the stock until revenue from Enbumyst and other initiatives ramps. MarketBeat / Zacks coverage on Esperion estimates

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.